<div
  id="info-orales-combinados"
  class="info-content hidden bg-white rounded-t-3xl"
>
  <div
    class="md:hidden bg-white rounded-lg overflow-hidden mb-6 "
  >
    <div
      class="bg-purple-abbott text-white p-4 text-center font-bold uppercase tracking-wide"
    >
      Anticonceptivos Orales Combinados
    </div>

    <div class="p-4 border-b border-gray-100">
      <span class="block text-black font-bold uppercase text-xs mb-1"
        >Cómo actúan</span
      >
      <p>Inhiben la ovulación</p>
    </div>

    <div class="p-4 border-b border-gray-100">
      <span class="block text-black font-bold uppercase text-xs mb-2"
        >Efectividad (Índice de Pearl)</span
      >
      <div class="flex gap-2">
        <div class="flex-1 p-3 rounded text-center">
          <span class="block text-2xl font-extrabold text-black">0,3</span>
          <span class="text-xs text-gray-600">Uso Correcto*</span>
        </div>
        <div class="flex-1 p-3 rounded text-center">
          <span class="block text-2xl font-extrabold text-black">7</span>
          <span class="text-xs text-gray-600">Uso Típico*</span>
        </div>
      </div>
    </div>

    <div class="p-4 border-b border-gray-100">
      <span class="block text-black font-bold uppercase text-xs mb-1"
        >Cuándo Iniciar</span
      >
      <p>
        En cualquier momento del mes.<br /><span class="text-xs text-gray-500"
          >>5 días desde el inicio de la menstruación, necesita método de respaldo por 7 días.</span>
      </p>
    </div>

    <div class="p-4">
      <span class="block text-black font-bold uppercase text-xs mb-1"
        >Modo de Uso</span
      >
      <p class="mb-2">Una píldora diaria a la misma hora.</p>
      <div class="text-xs text-gray-600 space-y-1">
        <p>• <strong>21 píldoras:</strong> descansa 7 días antes de iniciar el nuevo envase.</p>
        <p>• <strong>28 píldoras:</strong> uso continuo.</p>
      </div>
    </div>
  </div>

  <div class="overflow-x-auto px-2 md:px-0 rounded-t-3xl border border-purple-abbott">
    <table
      class="w-full border-collapse bg-white shadow-lg md:rounded-none rounded-lg overflow-hidden"
    >
      <thead class="hidden md:table-header-group text-white">
        <tr>
          <th
            colspan="7"
            class="bg-purple-abbott p-4 text-xl uppercase border-b-2 border-white"
          >
            Anticonceptivos Orales Combinados (AOC)
          </th>
        </tr>
        <tr class="bg-purple-abbott/70 text-xs uppercase">
          <th rowspan="2" class="border border-white p-2 border-b-purple-abbott border-l-purple-abbott">Cómo actúan</th>
          <th colspan="2" class="border border-white p-2"
            >Efectividad<sup>1</sup></th
          >
          <th rowspan="2" class="border border-white p-2 border-b-purple-abbott">Cuándo iniciar</th>
          <th rowspan="2" class="border border-white p-2 border-b-purple-abbott w-1/6">Modo / Frecuencia</th>
          <th rowspan="2" class="border border-white p-2 border-b-purple-abbott w-1/6">Opciones</th>
          <th rowspan="2" class="border border-white p-2 border-b-purple-abbott w-1/4"
            >Beneficios Adicionales</th
          >
        </tr>
        <tr class="bg-purple-abbott/70 text-xs uppercase">
          <th class="border border-white p-2 border-b-purple-abbott">Uso Correcto*</th>
          <th class="border border-white p-2 border-b-purple-abbott">Uso Típico*</th>
        </tr>
      </thead>

      <tbody class="block md:table-row-group">
        <tr
          class="flex flex-col md:table-row mb-4 md:mb-0 bg-white md:bg-transparent shadow md:shadow-none border border-purple-abbott md:border-none rounded-lg md:rounded-none overflow-hidden"
        >
          <td
            rowspan="13"
            class="hidden md:table-cell bg-purple-abbott/70 text-white font-bold text-center border border-purple-abbott p-3 text-lg align-middle"
          >
            Inhiben la ovulación
          </td>
          <td
            rowspan="13"
            class="hidden md:table-cell text-center border border-purple-abbott p-3 font-extrabold text-xl align-middle"
            >0,3</td
          >
          <td
            rowspan="13"
            class="hidden md:table-cell text-center border border-purple-abbott p-3 font-extrabold text-xl align-middle"
            >7</td
          >
          <td
            rowspan="13"
            class="hidden md:table-cell border border-purple-abbott p-4 align-middle"
          >
            <strong>En cualquier momento del mes:</strong><br /><br />
            <span class="text-xs"
              >>5 días desde el inicio de la menstruación, necesita método de respaldo por 7 días.</span
            >
          </td>
          <td
            rowspan="13"
            class="hidden md:table-cell border border-purple-abbott p-4 align-middle"
          >
            <strong>Una píldora diaria a la misma hora.</strong><br /><br />
            <span class="text-xs block mb-2"
              ><strong>21 píldoras:</strong> descansa 7 días antes de iniciar el nuevo envase.</span
            >
            <span class="text-xs block"
              ><strong>28 píldoras:</strong> no descansa entre un envase y otro.</span
            >
          </td>

          <td
            class="block md:table-cell p-4 md:text-black border border-purple-abbott text-center font-bold md:align-middle"
          >
            <span class="text-lg md:text-base">Bellanew</span>
            <span
              class="block text-xs font-normal text-purple-abbott/80 md:text-gray-500 mt-1"
              >(DNG 2mg / 17-β-estradiol 1,5 mg)</span
            >
          </td>
          <td
            class="block md:table-cell p-4 border border-purple-abbott  align-middle"
          >
            <span
              class="md:hidden text-black font-bold text-xs uppercase mb-2 block"
              >Beneficios:</span
            >
            <ul class="list-disc marker:text-[10px] text-xs md:text-sm">
              <li>Estrógeno bioidéntico al natural: menor riesgo de eventos adversos.<sup>2</sup></li>
              <li>Menor impacto metabólico.<sup>2</sup></li>
              <li>Potente actividad antiandrogénica (mejoría de acné, hirsutismo, piel y cabello grasos).<sup>3</sup></li>
            </ul>
          </td>
        </tr>

        <tr
          class="flex flex-col md:table-row mb-4 md:mb-0 bg-white md:bg-transparent shadow md:shadow-none border border-purple-abbott md:border-none rounded-lg md:rounded-none overflow-hidden"
        >
          <td
            class="block md:table-cell p-4 md: text-black border border-purple-abbott text-center font-bold md:align-middle"
          >
            <span class="text-lg md:text-base">Bellaface</span>
            <span
              class="block text-xs font-normal text-purple-abbott/80 md:text-gray-500 mt-1"
              >(DNG 2 mg / EE 30 mcg)</span
            >
          </td>
          <td
            class="block md:table-cell p-4 border border-purple-abbott  align-middle"
          >
            <span
              class="md:hidden text-black font-bold text-xs uppercase mb-2 block"
              >Beneficios:</span
            >
            <ul class="list-disc marker:text-[10px] text-xs md:text-sm">
              <li>Potente actividad antiandrogénica.<sup>3</sup></li>
              <li>Reducción de la intensidad y duración del sangrado menstrual.<sup>4</sup></li>
              <li>Mejoría dismenorrea.<sup>5</sup></li>
            </ul>
          </td>
        </tr>

        <tr
          class="flex flex-col md:table-row mb-4 md:mb-0 bg-white md:bg-transparent shadow md:shadow-none border border-purple-abbott md:border-none rounded-lg md:rounded-none overflow-hidden"
        >
          <td
            class="block md:table-cell p-4 md: text-black border border-purple-abbott text-center font-bold md:align-middle"
          >
            <span class="text-lg md:text-base">Bellaface suave</span>
            <span
              class="block text-xs font-normal text-purple-abbott/80 md:text-gray-500 mt-1"
              >(DNG 2 mg / EE 20 mcg)</span
            >
          </td>
          <td
            class="block md:table-cell p-4 border border-purple-abbott  align-middle"
          >
            <span
              class="md:hidden text-black font-bold text-xs uppercase mb-2 block"
              >Beneficios:</span
            >
            <ul class="list-disc marker:text-[10px] text-xs md:text-sm">
              <li>
                Potente actividad antiandrogénica con menos carga hormonal.<sup
                  >6</sup>
              </li>
              <li>Mayor tolerabilidad.<sup>6</sup></li>
            </ul>
          </td>
        </tr>

        <tr
          class="flex flex-col md:table-row mb-4 md:mb-0 bg-white md:bg-transparent shadow md:shadow-none border border-purple-abbott md:border-none rounded-lg md:rounded-none overflow-hidden"
        >
          <td
            class="block md:table-cell p-4 md:text-black border border-purple-abbott text-center font-bold md:align-middle"
          >
            <span class="text-lg md:text-base">Yax</span>
            <span
              class="block text-xs font-normal text-purple-abbott/80 md:text-gray-500 mt-1"
              >(DRSP 3 mg / EE 30 mcg)</span
            >
          </td>
          <td
            class="block md:table-cell p-4 border border-purple-abbott  align-middle"
          >
            <span
              class="md:hidden text-black font-bold text-xs uppercase mb-2 block"
              >Beneficios:</span
            >
            <ul class="list-disc marker:text-[10px] text-xs md:text-sm">
              <li>Propiedades antimineralocorticoides: sin impacto sobre el peso corporal.<sup>5</sup></li>
              <li>Mejoría de la dismenorrea.<sup>7</sup></li>
            </ul>
          </td>
        </tr>

        <tr
          class="flex flex-col md:table-row mb-4 md:mb-0 bg-white md:bg-transparent shadow md:shadow-none border border-purple-abbott md:border-none rounded-lg md:rounded-none overflow-hidden"
        >
          <td
            class="block md:table-cell p-4 text-black border border-purple-abbott text-center font-bold md:align-middle"
          >
            <span class="text-lg md:text-base">Yaxibelle</span>
            <span
              class="block text-xs font-normal text-purple-abbott/80 md:text-gray-500 mt-1"
              >(DRSP 3 mg / EE 20 mcg)</span
            >
          </td>
          <td
            class="block md:table-cell p-4 border border-purple-abbott  align-middle"
          >
            <span
              class="md:hidden text-black font-bold text-xs uppercase mb-2 block"
              >Beneficios:</span
            >
            <ul class="list-disc marker:text-[10px] text-xs md:text-sm">
              <li>Mejoría significativa de los síntomas del síndrome disfórico premenstrual (SDPM).<sup>7</sup></li>
              <li>Mejoría de la dismenorrea.<sup>7</sup></li>
            </ul>
          </td>
        </tr>

        <tr
          class="flex flex-col md:table-row mb-4 md:mb-0 bg-white md:bg-transparent shadow md:shadow-none border border-purple-abbott md:border-none rounded-lg md:rounded-none overflow-hidden"
        >
          <td
            class="block md:table-cell p-4 md:text-black border border-purple-abbott text-center font-bold md:align-middle"
          >
            <span class="text-lg md:text-base">Sinovul</span>
            <span
              class="block text-xs font-normal text-purple-abbott/80 md:text-gray-500 mt-1"
              >(LNG 150 mcg / 30 mcg)</span
            >
          </td>
          <td
            class="block md:table-cell p-4 border border-purple-abbott  align-middle"
          >
            <span
              class="md:hidden text-black font-bold text-xs uppercase mb-2 block"
              >Beneficios:</span
            >
            <ul class="list-disc marker:text-[10px] text-xs md:text-sm">
              <li>Mejoría y mantenimiento de la libido.<sup>5</sup></li>
              <li>Regulación del ciclo.<sup>5</sup></li>
            </ul>
          </td>
        </tr>

        <tr
          class="flex flex-col md:table-row mb-4 md:mb-0 bg-white md:bg-transparent shadow md:shadow-none border border-purple-abbott md:border-none rounded-lg md:rounded-none overflow-hidden"
        >
          <td
            class="block md:table-cell p-4 md:text-black border border-purple-abbott text-center font-bold md:align-middle"
          >
            <span class="text-lg md:text-base">Minipil</span>
            <span
              class="block text-xs font-normal text-purple-abbott/80 md:text-gray-500 mt-1"
              >(LNG 100 mcg / 20 mcg)</span
            >
          </td>
          <td
            class="block md:table-cell p-4 border border-purple-abbott  align-middle"
          >
            <span
              class="md:hidden text-black font-bold text-xs uppercase mb-2 block"
              >Beneficios:</span
            >
            <ul class="list-disc marker:text-[10px] text-xs md:text-sm">
              <li>Baja incidencia de efectos adversos.<sup>5</sup></li>
              <li>Regulación del ciclo.<sup>5</sup></li>
            </ul>
          </td>
        </tr>

        <tr
          class="flex flex-col md:table-row mb-4 md:mb-0 bg-white md:bg-transparent shadow md:shadow-none border border-purple-abbott md:border-none rounded-lg md:rounded-none overflow-hidden"
        >
          <td
            class="block md:table-cell p-4 md: text-black border border-purple-abbott text-center font-bold md:align-middle"
          >
            <span class="text-lg md:text-base">Facetix</span>
            <span
              class="block text-xs font-normal text-purple-abbott/80 md:text-gray-500 mt-1"
              >(CPA 2 mg / EE 35 mcg)</span
            >
          </td>
          <td
            class="block md:table-cell p-4 border border-purple-abbott  align-middle"
          >
            <span
              class="md:hidden text-black font-bold text-xs uppercase mb-2 block"
              >Beneficios:</span
            >
            <ul class="list-disc marker:text-[10px] text-xs md:text-sm">
              <li>Potencia antiandrogénica mayor, en relación con otros progestágenos. Alta eficacia en la reducción del SAHA (seborrea, acné, hirsutismo y alopecia). Ayuda a la reducción de los riesgos del SOP a corto y largo plazo.<sup>6,7</sup></li>
            </ul>
          </td>
        </tr>

        <tr
          class="flex flex-col md:table-row mb-4 md:mb-0 bg-white md:bg-transparent shadow md:shadow-none border border-purple-abbott md:border-none rounded-lg md:rounded-none overflow-hidden"
        >
          <td
            class="block md:table-cell p-4 md: text-black border border-purple-abbott text-center font-bold md:align-middle"
          >
            <span class="text-lg md:text-base">Facetix suave</span>
            <span
              class="block text-xs font-normal text-purple-abbott/80 md:text-gray-500 mt-1"
              >(CPA 2 mg / EE 30 mcg)</span
            >
          </td>
          <td
            class="block md:table-cell p-4 border border-purple-abbott  align-middle"
          >
            <span
              class="md:hidden text-black font-bold text-xs uppercase mb-2 block"
              >Beneficios:</span
            >
            <ul class="list-disc marker:text-[10px] text-xs md:text-sm">
              <li>Eficacia en el tratamiento del hiperandrogenismo femenino o síntomas cutáneos del SOP, con menor carga estrogénica.<sup>7</sup></li>
            </ul>
          </td>
        </tr>

        <tr
          class="flex flex-col md:table-row mb-4 md:mb-0 bg-white md:bg-transparent shadow md:shadow-none border border-purple-abbott md:border-none rounded-lg md:rounded-none overflow-hidden"
        >
          <td
            class="block md:table-cell p-4 md: text-black border border-purple-abbott text-center font-bold md:align-middle"
          >
            <span class="text-lg md:text-base">Gynorelle 30</span>
            <span
              class="block text-xs font-normal text-purple-abbott/80 md:text-gray-500 mt-1"
              >(CMA 2 mg / EE 30 mcg)</span
            >
          </td>
          <td
            class="block md:table-cell p-4 border border-purple-abbott  align-middle"
          >
            <span
              class="md:hidden text-black font-bold text-xs uppercase mb-2 block"
              >Beneficios:</span
            >
            <ul class="list-disc marker:text-[10px] text-xs md:text-sm">
              <li>Beneficio en los estados de ánimo, sin efecto deletéreo sobre la libido. Reducción de la dismenorrea.<sup>8</sup></li>
            </ul>
          </td>
        </tr>

        <tr
          class="flex flex-col md:table-row mb-4 md:mb-0 bg-white md:bg-transparent shadow md:shadow-none border border-purple-abbott md:border-none rounded-lg md:rounded-none overflow-hidden"
        >
          <td
            class="block md:table-cell p-4 md: text-black border border-purple-abbott text-center font-bold md:align-middle"
          >
            <span class="text-lg md:text-base">Gynorelle</span>
            <span
              class="block text-xs font-normal text-purple-abbott/80 md:text-gray-500 mt-1"
              >(CMA 2 mg / EE 20 mcg)</span
            >
          </td>
          <td
            class="block md:table-cell p-4 border border-purple-abbott  align-middle"
          >
            <span
              class="md:hidden text-black font-bold text-xs uppercase mb-2 block"
              >Beneficios:</span
            >
            <ul class="list-disc marker:text-[10px] text-xs md:text-sm">
              <li>Reducción significativa de los síntomas emocionales (estados de ánimo depresivos) y físicos relacionados con el ciclo menstrual, con baja dosis hormonal.<sup>9</sup></li>
            </ul>
          </td>
        </tr>

        <tr
          class="flex flex-col md:table-row mb-4 md:mb-0 bg-white md:bg-transparent shadow md:shadow-none border border-purple-abbott md:border-none rounded-lg md:rounded-none overflow-hidden"
        >
          <td
            class="block md:table-cell p-4 md: text-black border border-purple-abbott text-center font-bold md:align-middle"
          >
            <span class="text-lg md:text-base">Evely</span>
            <span
              class="block text-xs font-normal text-purple-abbott/80 md:text-gray-500 mt-1"
              >(E2V/DNG)</span
            >
          </td>
          <td
            class="block md:table-cell p-4 border border-purple-abbott  align-middle"
          >
            <span
              class="md:hidden text-black font-bold text-xs uppercase mb-2 block"
              >Beneficios:</span
            >
            <ul class="list-disc marker:text-[10px] text-xs md:text-sm">
              <li>Aprobación de la FDA para el tratamiento del sangrado menstrual abundante. No afecta la libido.<sup>10,11</sup></li>
            </ul>
          </td>
        </tr>

        <tr
          class="flex flex-col md:table-row mb-4 md:mb-0 bg-white md:bg-transparent shadow md:shadow-none border border-purple-abbott md:border-none rounded-lg md:rounded-none overflow-hidden"
        >
          <td
            class="block md:table-cell p-4 md: text-black border border-purple-abbott text-center font-bold md:align-middle"
          >
            <span class="text-lg md:text-base">Femelle 20CD</span>
            <span
              class="block text-xs font-normal text-purple-abbott/80 md:text-gray-500 mt-1"
              >(DRSP 3 mg / EE 20 mcg)</span
            >
          </td>
          <td
            class="block md:table-cell p-4 border border-purple-abbott  align-middle"
          >
            <span
              class="md:hidden text-black font-bold text-xs uppercase mb-2 block"
              >Beneficios:</span
            >
            <ul class="list-disc marker:text-[10px] text-xs md:text-sm">
              <li>Eficacia en el manejo de los síntomas del síndrome disfórico premenstrual.<sup>12</sup></li>
            </ul>
          </td>
        </tr>
      </tbody>
    </table>
  </div>

  <div class="mt-4 p-4">
    <div class="text-xs text-gray-600 space-y-1">
      <p>*Tasa de embarazo en el primer año de uso.</p>
      <p><strong>CMA:</strong> acetato de clormadinona; <strong>CPA:</strong> acetato de ciproterona; <strong>DNG:</strong> dienogest; <strong>DRSP:</strong> drospirenona; <strong>E2V:</strong> valerato de estradiol; <strong>EE:</strong> etinilestradiol; <strong>LNG:</strong> levonorgestrel; <strong>SOP:</strong> síndrome de ovario poliquístico.</p>
    </div>
    <div class="mt-2">
      <strong>Referencias:</strong> <strong>1.</strong> Organización Mundial de la Salud (OMS). Planificación familiar. Un manual para proveedores [Internet]. OMS; 2019. Disponible en: https://bit.ly/2B50Pnw <strong>2.</strong> Alsina JC. After 50 years of ethinylestradiol, another oestrogen in combined oral contraceptives. The European Journal of Contraception and Reproductive Health Care. 2010;15:1–3. 3. Pérez E. Ethinylestradiol/Dienogest in Oral Contraception 2010. Drugs. 2010;70 (6):681-9. 4. Mahapatra PC, Khandke D, Patil D. Ethinyl Estradiol + Dienogest. Indian Pract. 2019;72(11):29-31. 5. Vásquez-Awad D, Palacios S, De Melo N, Gómez-Tabares G, Loret de Mola R. Anticonceptivos orales combinados (AOC). Guías latinoamericanas. Medicina (Bogotá). 2014;36(2):136-149. 6. Ruan X, Kubba A, Aguilar A, Mueck AO. Use of cyproterone acetate/ethinylestradiol in polycystic ovary syndrome: rationale and practical aspects. Eur J Contracept Reprod Health Care. 2017;22(3):183-190. 7. Bitzer J, Römer T, Lopes da Silva Filho A. The use of cyproterone acetate/ethinyl estradiol in hyperandrogenic skin symptoms - a review. Eur J Contracept Reprod Health Care. 2017 Jun;22(3):172-182. 8. Zahradnik H, Hanjalic A, Schilling A. Beneficios no anticonceptivos de 0,02 mg de etinilestradiol/2 mg de acetato de clormadinona administrados en un régimen de 24+4 días. Rev Chil Obstet Ginecol. 2011;76(5):344-353. 9. Barriga P P, Ambrosi Penazzo N, Franco Finotti M, Celis AA, Cerdas O, Chávez JA, Cuitiño LA, Fernandes CE, Plata MA, Tirán-Saucedo J, Vanhauwaert PS. At 10 years of chlormadinone use in Latin America: a review. Gynecol Endocrinol. 2016;32(7):517-20. 10. Micks EA, Jensen JT. Treatment of heavy menstrual bleeding with the estradiol valerate and dienogest oral contraceptive pill. Adv Ther. 2013 Jan;30(1):1-13.  11. Davis SR, Bitzer J, Giraldi A, Palacios S, Parke S, Serrani M, Mellinger U, Nappi RE. Change to either a nonandrogenic or androgenic progestin-containing oral contraceptive preparation is associated with improved sexual function in women with oral contraceptive-associated sexual dysfunction. J Sex Med. 2013 Dec;10(12):3069-79. 12. Marr J, et al. Ethinyl estradiol 20 μg/drospirenone 3 mg 24/4 oral contraceptive for the treatment of functional impairment in women with premenstrual dysphoric disorder. Int J Gynecol Obst 2011; 113: 103-7. 13. Wongwananuruk T, Panichyawat N, Panchalee T, et al. Comparison of change in body weight between contraception containing 30-μg ethinylestradiol/2-mg chlormadinone acetate or 30-μg ethinylestradiol/3-mg drospirenone: a randomised controlled trial. Eur J Contracept Reprod Health Care. 2020;25(1):43-48.
    </div>
  </div>
</div>
